AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00006042
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02319161
Drug: Calcium channel blocker and beta blocker
RxNorm normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients in which systolic blood pressure increased to 150 mmHg and above following tourniquet inflation and in which a bolus dose of calcium channel blocker 10 mg (Diltizem, Mustafa Nevzat İlaç Sanayi Aş) (Group I) or beta blocker 0.5mg/kg (Brevibloc, Eczacıbaşı İlaç Sanayi Aş) (Group II) were administered intravenously constituted the study groups.
Trial: NCT00519376
Drug: GW642444M
FDA approved: no
EMA approved: no
PMDA approved: no
Description: drug
Trial: NCT00519376
Drug: GW642444H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: drug
Trial: NCT00519376
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03729258
Drug: Infex 400 MR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infex (cefpodoxime) 400mg once a day (QD) for 10 days
Trial: NCT03729258
Drug: Infex 200 IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infex (cefpodoxime) 200mg twice a day (BID) for 10 days
Trial: NCT02321293
Drug: Tyrosine Kinase Inhibitor gefitinib (Iressa)
RxNorm normalized name: gefitinib Oral Tablet [Iressa]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg PO daily until progression
Trial: NCT04301479
Drug: hydrocortisone sodium succinate
RxNorm normalized name: Hydrocortisone Sodium Succinate
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Steroid group will receive 200 mg of hydrocortisone diluted in 120 mL of saline at an infusion rate of 5mL/hr for 3 days or shock reversal
Trial: NCT02321293
Drug: Tyrosine Kinase Inhibitor erlotinib (Tarceva)
RxNorm normalized name: erlotinib Oral Tablet [Tarceva]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg PO daily until progression
Trial: NCT03305419
Drug: GSK2982772 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2982772 will be available as size 00, white, opaque capsule containing white to almost white Solid (120 mg maximum fill per capsule). It will be administered orally with water to receive total dose of 120 mg, 240 mg or 360 mg per randomization.
Trial: NCT03305419
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be available as size 00, white, opaque capsule containing white to almost white Solid. It will be administered orally with water.
Trial: NCT00834990
Drug: Depakote®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: delayed-release 500 mg tablet
Trial: NCT00988364
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 20mg daily for 3 months.
Trial: NCT00988364
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo one tablet daily times 3 months.
Trial: NCT03295383
Drug: Cyclophosphamide 50Mg Oral Tablet
RxNorm normalized name: Cyclophosphamide 50mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cyclophosphamide will be administered orally once daily at the following initial doses:~* patients younger than 75 years: 1.5 mg/kg/day, orally.~* patients older than 75 years: 1 mg/kg/day, orally.
Trial: NCT03295383
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cyclophosphamide placebo will be administered orally once daily
Trial: NCT01235923
Drug: three times weekly Epo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epo 400 units/kg administered subcutaneously three times per week for a total of 4 weeks
Trial: NCT00521599
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02609230
Drug: ONC-201
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02312804
Drug: BGJ398
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGJ398 will be administered orally once daily on each day of the 21 day cycle.
Trial: NCT03585036
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure
Trial: NCT02604654
Drug: Yiqitongluo granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered after dissolved
Trial: NCT00004495
Drug: folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004495
Drug: pyridoxine
RxNorm normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03061721
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomly assigned to this group will receive placebo tablet orally once daily for 16 weeks.
Trial: NCT03447314
Drug: GSK1795091
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1795091 will be available as solution for injection
Trial: NCT03447314
Drug: GSK3174998
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3174998 will be available as lyophilized powder to be reconstituted for infusion.
Trial: NCT03447314
Drug: GSK3359609
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3359609 will be available as solution for infusion.
Trial: NCT01083979
Drug: Liposomes
RxNorm normalized name: liposomes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical instillation
Trial: NCT02082457
Drug: YKP10811 5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02082457
Drug: YKP10811 20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02082457
Drug: YKP10811 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00434083
Drug: naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01168791
Drug: doxorubicin in combination with palifosfamide-tris
FDA approved: no
EMA approved: no
PMDA approved: no
Description: palifosfamide-tris: 150 mg/m2 3 days every 21 days for a maximum of 6 cycles.~doxorubicin: 75 mg/m2 1 day every 21 days for a maximum of 6 cycles.
Trial: NCT01168791
Drug: doxorubicin in combination with placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doxorubicin: 75 mg/m2 of doxorubicin 1 day every 21 days for a maximum of 6 cycles.~placebo: 250 mL of normal saline 3 days every 21 days for a maximum of 6 cycles.
Trial: NCT00309699
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily for 3 weeks
Trial: NCT04319380
Drug: SMC placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Year 1 and 2 (2020/21) Four cycles of SMC placebo (July, August, September, October)
Trial: NCT01713283
Drug: SOF
RxNorm normalized name: Kasof
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily
Trial: NCT00812006
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to rizatriptan 10 mg ODT orally for a moderate or severe migraine attack
Trial: NCT00937144
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02130713
Drug: Third generation fluoroquinolone
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prulifloxacin 600 mg
Trial: NCT01571050
Drug: Fresh MFP/CaCO3 toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingestion of 31.9 mg of a fresh toothpaste containing 1450 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight.
Trial: NCT01571050
Drug: Fresh NaF/SiO2 toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingestion of 49.5 mg of a fresh toothpaste containing 1100 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight.
Trial: NCT01571050
Drug: Aged NaF/SiO2 toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingestion of 49.5 mg of a toothpaste containing 1100 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight. The toothpaste had been previously aged to simulate one year storage at room temperature.
Trial: NCT01571050
Drug: Aged MFP/CaCO3 toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingestion of 31.9 mg of a toothpaste containing 1450 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight. The toothpaste had been previously aged to simulate one year storage at room temperature.
Trial: NCT01939002
Drug: BIIB017
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01939002
Drug: naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01133405
Drug: LY2886721
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules
Trial: NCT01133405
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules
Trial: NCT02629848
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motesanib placebo-matching tablets
Trial: NCT00433160
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily, subcutaneous
Trial: NCT00075725
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00075725
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00075725
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00075725
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00075725
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT or IV
Trial: NCT02499900
Drug: Copaxone®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Injections
Trial: NCT03222973
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm
Trial: NCT00395135
Drug: Matching Placebo BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet each morning and evening for a duration of 52 or 104 weeks.
Trial: NCT03073018
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral administration, capsules
Trial: NCT03073018
Drug: Pravastatin Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration, capsules
Trial: NCT00492479
Drug: Kinerase Pro+Therapy Line day repair, serum, night repair
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00492479
Drug: Kinerase Pro+Therapy Line Ultra rich day repair
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01438801
Drug: Nutropin [Somatropin (rDNA origin) for injection]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doses in the diagnostic protocol are 0.7 and 1.4 mg/m2/day, injected by subcutaneous injection at bedtime for 2 weeks, divided by washout periods of preferably 4 weeks (accepted range 4-6 weeks). An additional period of 2 weeks on 2.8 mg/m2/day (after a washout period of 4-6 weeks) will be added if the IGF-I response on either dosage is insufficient (serum IGF-I SDS \<0).
Trial: NCT01792375
Drug: 10mg Dinoprostone vaginal insert
RxNorm normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For women assigned to No sweep: The only 10mg Dinoprostone vaginal insert were placed in the posterior fornix for cervical ripening
Trial: NCT04627675
Drug: CORVax
RxNorm normalized name: SARS-COV-2 COVID-19 PS Non-US Vaccine (Biological E Limited, Corbevax)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNA-encodable coronaviral vaccine
Trial: NCT04627675
Drug: IL-12 plasmid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cytokine
Trial: NCT03224403
Drug: Test acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of 2 Test acetaminophen 500 mg tablets
Trial: NCT03224403
Drug: Commercial acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of 2 acetaminophen 500 mg caplets
Trial: NCT03224403
Drug: Commercial ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single dose of 2 ibuprofen 200 mg Liquid-filled Capsules
Trial: NCT03224403
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 placebo caplets
Trial: NCT03165123
Drug: Oral Azithromycin tablet
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral azithromycin tablet will be given one hour before induction of anaesthesia.
Trial: NCT06461598
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All adjuvant chemotherapy for nonmetastatic PDAC was gemcitabine-based (Cycle \>= 1).
Trial: NCT03511625
Drug: Acthar Injectable Product
RxNorm normalized name: Acthar Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acthar is a non-specific melanocortin receptor agonist
Trial: NCT03304054
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets matching amifampridine phosphate, 3 to 4 times a day
Trial: NCT02727387
Drug: TEMIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Window therapy frontline for VHR patients
Trial: NCT02727387
Drug: CYC
RxNorm normalized name: Cycrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug used in the Induction phase in association with Vincristine, Ifosfamide, Adriamycin and Etoposide
Trial: NCT02727387
Drug: BUMEL
RxNorm normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Consolidation phase
Trial: NCT02727387
Drug: VIN
RxNorm normalized name: Ravin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug used in the Induction phase in association with cyclophosphamide , Ifosfamide, Adriamycin and Etoposide
Trial: NCT02968160
Drug: Telmisartan 40mg + Rosuvastatin 20mg
RxNorm normalized name: telmisartan 40 MG
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02968160
Drug: Telmisartan 80mg + Rosuvastatin 20mg
RxNorm normalized name: telmisartan 80 MG
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02968160
Drug: Rosuvastatin 20mg
RxNorm normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02791191
Drug: LY3202626
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02791191
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT03985982
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection, sodium chloride 0.9 % divided in five 0.1 mL i.m injections into the glabellar area
Trial: NCT00230802
Drug: Anticipatory dose increase of levothyroxine
RxNorm normalized name: combinations of levothyroxine and liothyronine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: as it is know that levothyroxine requirement increases in pregnancy, both study arms will increase levothyroxine dose, though by different amounts.
Trial: NCT00230802
Drug: levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients will increase levothyroxine dosage by 2 extra tablets of their current dose per week
Trial: NCT00230802
Drug: levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients will increase levothyroxine by 3 extra tablets of their current dose per week.
Trial: NCT03165240
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Film-coated tablet
Trial: NCT03165240
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet
Trial: NCT01428037
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet vaginal inserted at 4 hrly interval with maximum of three doses
Trial: NCT00258232
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00258232
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01981863
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered in same volume as in experimental arm.
Trial: NCT00004248
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00731653
Drug: Combination Product: BCI-024 + BCI-049
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCI-024 and BCI-049 once a day at bedtime for 6 weeks
Trial: NCT00000273
Drug: opiates
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prescription opioids
Trial: NCT03012100
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT00269269
Drug: antihypertensive drug
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03788018
Drug: saline IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received 20 ml normal saline and 20 ml normal saline in the CON group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion 20 ml normal saline and 20 ml normal saline every hour until 30 min before the end of surgery
Trial: NCT04051710
Drug: Test Product
RxNorm normalized name: Patch test product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
Trial: NCT04051710
Drug: Reference Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
Trial: NCT04051710
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Product
Trial: NCT01791881
Drug: Hugeltox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25U\~2.5U/site, Maximum dosage 12.5U\~60U/person
Trial: NCT00801034
Drug: Calcium
RxNorm normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets, 1 tablet 2 times per day in 28 days
Trial: NCT02926326
Drug: BCT197
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of BCT197
Trial: NCT02926326
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 daily doses of Azithromycin
Trial: NCT00309712
Drug: simvastatin 20 mg and placebo
RxNorm normalized name: simvastatin 20 MG
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00309712
Drug: fenofibrate 160 mg and simvastatin 20 mg
RxNorm normalized name: simvastatin and fenofibrate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02284529
Drug: Orectalip
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 85mg/m2 in D5W 250 ml IV drip 2hrs on D1, Leucovorin 100mg/m2 in N/S 100ml IV drip 2hrs on D1, follow by 5-FU 2400mg/m2 IV infusion 24hrs on D1
Trial: NCT01832129
Drug: Oral administration of vitamin B12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily high dose oral vitamin B12 (1mg) will be administered over 4 weeks. The patients adherence to this regimen will be monitored with an electronic punch card.
Trial: NCT01832129
Drug: i.m. injection of vitamin B12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injections of 1 mg vitamin B12 will be performed at days 7, 14, and 21.
Trial: NCT03389555
Drug: vitamin C, vitamin B1, hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (1.5g) plus vitamin B1 (100mg) will be diluted in 100ml 0.9% NACL(normal saline) and administered IV every 6 hours for 4 days or until participant is discharged from the ICU. Hydrocortisone 50mg/ml will be administered via IV push over 1-2 minutes every 6hours for 4 days or until the patient is discharged from the ICU.
Trial: NCT03389555
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (0.9% NaCl solution) volume to match all components
Trial: NCT03806556
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV medication administered after patient meets inclusion/exclusion criteria
Trial: NCT03224507
Drug: KRdD followed by auto-HCT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosages of each drug will vary depending on therapy type and cycle number. KRdD therapy will be followed by autologous hematopoietic cell transplantation and KRdD consolidation.
Trial: NCT03224507
Drug: KRdD only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosages of each drug will vary depending on therapy type and cycle number. KRdD therapy will not be followed by autologous hematopoietic cell transplantation but will proceed with KRdD consolidation.
Trial: NCT00685269
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet